HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.

@article{BrunVzinet1997HIV1VL,
  title={HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.},
  author={Françoise Brun-V{\'e}zinet and Charles A. B. Boucher and Clive Loveday and Diane Descamps and Vincent Fauveau and Jacques Izopet and David Jeffries and Stephen Kaye and C Krzyanowski and Andrew Nunn and Rob Schuurman and J. M. Seigneurin and Catherine Tamalet and Richard J Tedder and Jutta Weber and Gerrit Jan Weverling},
  journal={Lancet},
  year={1997},
  volume={350 9083},
  pages={983-90}
}
BACKGROUND The Delta trial showed that combination therapy (zidovudine plus didanosine and zidovudine plus zalcitabine) substantially lengthened life and reduced disease progression compared with zidovudine monotherapy. We did a nested virological study in three countries (France, the Netherlands, and the UK) to investigate changes in markers for viral load… CONTINUE READING